



1600 20th Street, NW • Washington, D.C. 20009 • 202/588-1000 • www.citizen.org

Kenneth C. Frazier
Chairman of the Board and Chief Executive Officer
Merck & Co.
One Merck Drive
P.O. Box 100
Whitehouse Station, NJ 08889-0100

April 8, 2014

Dear Mr. Frazier,

Please find enclosed Public Citizen's press release concerning the Medicine Patent Pool's latest licensing agreement with ViiV Healthcare for the new treatment for HIV, dolutegravir. Pro-competitive licensing agreements that are broad in geographic scope are essential for reducing costs and expanding access to treatment. We request that Merck join other patent holders that have negotiated licenses with the Medicines Patent Pool by initiating negotiations with the Pool to license efavirenz and raltegravir. Thank you for your consideration.

Sincerely,

A handwritten signature in black ink that reads "Peter Maybarduk".

Peter Maybarduk
Global Access to Medicines Program, Director
Public Citizen
1-202-588-7755
pmaybarduk@citizen.org

Enclosure(s): 1